Lung Cancer-Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg-Dependent...

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Tumor cell-intrinsic pathways significantly impact the tumor immune microenvironment, influencing tumor progression and immunotherapy resistance.
• Exclusion of immune cells, particularly cytotoxic T cells, from the tumor core is a key mechanism of immune evasion.
• Understanding these pathways is crucial for developing effective cancer therapies.

Purpose of the Study:

• To investigate the role of tumor cell-intrinsic SOX2 signaling in non-small cell lung cancer (NSCLC).
• To elucidate the mechanism by which SOX2 signaling affects cytotoxic T-cell infiltration and immunotherapy resistance.
• To evaluate the therapeutic potential of targeting SOX2-mediated immune evasion.

Main Methods:

• Analysis of SOX2 signaling in NSCLC tumor cells.
• Assessment of immune cell infiltration, including CD8+ T cells and regulatory T cells (Tregs).
• Investigation of the role of CCL2 and tumor vasculature in T-cell exclusion.
• Experimental depletion of tumor-infiltrating Tregs and combination therapy with checkpoint blockade.

Main Results:

• Tumor cell-intrinsic SOX2 signaling in NSCLC promotes the exclusion of cytotoxic T cells from the tumor core.
• SOX2 upregulates CCL2, leading to increased recruitment of Tregs, which suppress tumor vasculature and mediate CD8+ T-cell exclusion.
• Depletion of Tregs restored CD8+ T-cell infiltration.
• Combined Treg depletion and checkpoint blockade therapy significantly reduced tumor growth.

Conclusions:

• Tumor cell-intrinsic SOX2 expression is a novel mechanism of immunotherapy resistance in NSCLC.
• Targeting SOX2-induced Treg recruitment and subsequent CD8+ T-cell exclusion presents a potential therapeutic strategy.
• Further investigation is warranted to determine if NSCLC patients with SOX2-dependent CD8+ T-cell exclusion benefit from Treg depletion therapies.